跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RSL3
首页
药物
RSL3
RSL3
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Application of ferroptosis agonist RSL3 in preparation of radiotherapy sensitizer
申请人: UNIV JILIN
优先权: 2024
CN
Application of ferroptosis inducer RSL3 in preparation of medicine for inhibiting glioblastoma
申请人: FIRST AUXILIARY HOSPITAL OF CHINESE PEOPLE LIBERATION ARMY LAND ARMY AND MILITARY UNIV
优先权: 2022
CN
Application of RSL3 combined adriamycin in preparation of medicine for treating breast cancer
申请人: FIRST HOSPITAL JILIN UNIV
优先权: 2024
CN
Application of ferroptosis inducer RSL3 in preparation of medicine for treating gastrointestinal stromal tumor
申请人: ZHONGSHAN HOSPITAL FUDAN UNIV
优先权: 2023
CN
Application of combination of RSL3 and chemotherapeutic drugs in preparation of drugs for treating tumors
申请人: SHANGHAI CHANGZHENG HOSPITAL
优先权: 2023
CN
Application of ferroptosis inducer RSL3 in preparation of product for preventing and/or treating hypertrophic scars
申请人: UNIV NINGXIA MEDICAL
优先权: 2023
CN
铁死亡诱导剂RSL3的应用及治疗肝癌药物
申请人: 中国科学院大连化学物理研究所
优先权: 2019
CN
Application of combination of ferroptosis promoter RSL3 and imatinib in preparation of medicine for treating gastrointestinal stromal tumor
申请人: ZHONGSHAN HOSPITAL FUDAN UNIV
优先权: 2023
CN
药物
反馈